EYPT Stock Cash Flow Statements

EyePoint Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

EyePoint Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30

cash flows from operating activities:
net income	-59,426,000	-45,195,000	-41,399,000	-29,361,000	-30,826,000	-29,284,000	-14,099,000	-12,612,000	-22,920,000	-21,164,000	-43,452,000	-18,420,000	-19,406,000	-20,976,000	-19,432,000	-16,695,000	-10,010,000	-12,280,000	-15,469,000	-3,801,000	-12,950,000	-13,174,000	-10,410,000	-15,647,000	-11,498,000	-19,238,000	-33,126,000	-34,428,000	-6,978,000	-5,782,000	-5,983,000	-6,116,000	-5,140,000	-67,000	-7,162,000	-6,387,000	-5,041,000	-5,186,000	-4,933,000	-5,146,000	-4,998,000	-4,075,000	20,566,000	-3,967,000	-2,187,000	-3,514,000	-3,687,000	-3,947,000	-2,794,000	-2,608,000	-2,551,000	-2,262,000	-2,686,000	-17,460,000	-2,427,000	-140,000	-2,685,000	13,073,000	-2,705,000	-24,000	-1,591,000	-534,000	-636,000	-870,000	-471,000	-63,579,000	-5,501,000	140,837,000	-147,427,000
adjustments to reconcile net income to cash flows used in operating activities:
depreciation of property and equipment	538,000	497,000			362,000	303,000	112,000	115,000	132,000	105,000	130,000	96,000	89,000	81,000	83,000	86,000	70,000	72,000	54,000	47,000	55,000	33,000	35,000	31,000	34,000	44,000	43,000	41,000	43,000	44,000	39,000	32,000	27,000	26,000	6,000	64,000	29,000	30,000	29,000	33,000	22,000	22,000	35,000	36,000	35,000	29,000	39,000	57,000	57,000	56,000	55,000	78,000	44,000	44,000	24,000	15,000	15,000	10,000	8,000	9,000	10,000	13,000	24,000	30,000	35,000
amortization of debt discount and premium and discount on available-for-sale marketable securities	-1,201,000	-1,733,000	-1,810,000	-1,876,000	-1,692,000	-575,000	-522,000	-39,000	-51,000	-244,000	-340,000	-214,000	-114,000	110,000
stock-based compensation	6,876,000	7,820,000	7,900,000	7,446,000	8,695,000	12,699,000	3,590,000	3,629,000	1,788,000	3,050,000	3,361,000	3,199,000	4,140,000	3,477,000	2,808,000	2,471,000	1,180,000	988,000	1,263,000	2,389,000	735,000	1,160,000	857,000	977,000	1,496,000	1,238,000
deferred income tax
changes in operating assets and liabilities:
accounts receivable and other current assets	-180,000	3,428,000	1,863,000	-939,000	3,092,000	-4,260,000	-269,000	10,748,000	-979,000	4,932,000	6,280,000	368,000	-6,373,000	-2,937,000	-5,981,000	1,321,000	-3,626,000	-2,317,000	2,352,000	-1,978,000	6,792,000	-2,320,000	-4,623,000	0	-8,635,000	-2,046,000	-529,000		-249,000	-55,000	129,000		-87,000	-52,000	8,000		-236,000	384,000	136,000		230,000	24,705,000	-25,323,000		319,000	1,154,000	-457,000		-432,000	163,000	147,000		-250,000	-168,000	206,000		-48,000		-231,000	201,000	100,000
other assets	-18,000	-44,000	-3,410,000
inventory	-549,000	176,000	502,000	865,000	584,000	-351,000	671,000	-315,000	-724,000	-1,185,000	-845,000	-277,000	82,000	280,000	580,000	810,000	205,000	-248,000	-1,697,000	132,000	-414,000	-1,221,000	421,000	-888,000	-785,000	-607,000
accounts payable and accrued expenses	-3,470,000	4,974,000	8,133,000	-6,038,000	5,066,000	-1,430,000	728,000	-2,889,000	5,947,000	-2,267,000	-483,000	1,771,000	2,017,000	-2,107,000	3,446,000	3,676,000	3,152,000	-1,798,000	1,283,000	2,931,000	-398,000	-1,944,000	1,115,000	-345,000	1,233,000	2,593,000	756,000		-135,000	-525,000	-972,000		-283,000	99,000	-240,000		87,000	898,000	-350,000		-9,000	-5,000	235,000		475,000	-870,000	-438,000		501,000	286,000	-2,000		205,000	-357,000	-373,000		109,000		48,000	-214,000	-123,000		260,000	-343,000	-2,498,000		-4,224,000	-6,978,000	6,547,000
right-of-use assets and operating lease liabilities	64,000	479,000	407,000	672,000	15,000	524,000	-506,000	82,000	192,000	193,000	113,000	-34,000	25,000	-35,000	-34,000	80,000	-36,000	-38,000	117,000	-15,000	-27,000	-3,000	-1,000	3,000	9,000	35,000
deferred revenue	-5,115,000	-23,522,000	-8,592,000	-7,783,000	-5,474,000	-8,797,000	-12,897,000	-13,923,000	71,598,000	-255,000	-205,000	-240,000	-198,000	-225,000	-197,000	-313,000	-181,000	-240,000	16,261,000	300,000	-30,000	15,000	15,000	0	0	-30,000		-240,000	-265,000	495,000	-40,000	-206,000	120,000	-3,000	-8,000	128,000	-8,000	-9,000	-8,000	9,000	-34,000	-34,000	-35,000	23,000	-1,140,000	510,000	340,000	-103,000	164,000	-176,000	150,000	-195,000	-89,000	-181,000	-1,430,000	-558,000	-21,000	481,000	441,000	-2,472,000	-1,977,000	-2,264,000	-2,235,000	-1,561,000	-1,828,000	-1,842,000	18,953,000	-1,791,000	1,613,000
other noncurrent liabilities
net cash from operating activities	-62,589,000	-53,120,000	-35,849,000	-39,028,000	-20,178,000	-31,171,000	-23,109,000	-15,204,000	57,023,000	-16,835,000	-12,588,000	-13,136,000	-19,123,000	-20,158,000	-16,668,000	-7,787,000	-10,543,000	-15,099,000	5,895,000	1,136,000	-5,121,000	-16,345,000	-11,486,000	-14,772,000	-17,107,000	-13,334,000	-11,766,000	-6,081,000	-4,820,000	-5,038,000	-5,968,000	-4,452,000	-4,543,000	-5,009,000	-6,486,000	-4,347,000	-4,302,000	-3,174,000	-4,493,000	-3,006,000	-3,954,000	21,251,000	-3,994,000	-2,785,000	-1,852,000	-2,257,000	-3,777,000	-3,380,000	-1,962,000	-1,782,000	-1,621,000	-1,838,000	-2,143,000	-2,360,000	-2,660,000	1,245,000	-1,613,000	13,608,000	-1,461,000	-1,323,000	-925,000	-1,140,000	-1,853,000	-957,000	-4,486,000
capex	-1,220,000	-276,000	-384,000	-1,574,000	-900,000	-1,194,000	-883,000	-1,720,000	-396,000	-484,000	-585,000	-1,198,000	-218,000	-149,000	0	-131,000	0	0	-192,000	-128,000	-26,000	-16,000	-6,000	0	-25,000	-182,000	-109,000	-45,000	1,000	0	-64,000	-126,000	-16,000	0	0	-46,000	-31,000	-25,000	-11,000	-90,000	-43,000	-22,000	-6,000	-173,000	-54,000	-13,000	-8,000	-19,000	-13,000	-32,000	-4,000	-6,000	-19,000	-159,000	-221,000	-65,000	-9,000	0	0	0	0	-21,000	-18,000	-49,000	-107,000
free cash flows	-63,809,000	-53,396,000	-36,233,000	-40,602,000	-21,078,000	-32,365,000	-23,992,000	-16,924,000	56,627,000	-17,319,000	-13,173,000	-14,334,000	-19,341,000	-20,307,000	-16,668,000	-7,918,000	-10,543,000	-15,099,000	5,703,000	1,008,000	-5,147,000	-16,361,000	-11,492,000	-14,772,000	-17,132,000	-13,516,000	-11,875,000	-6,126,000	-4,819,000	-5,038,000	-6,032,000	-4,578,000	-4,559,000	-5,009,000	-6,486,000	-4,393,000	-4,333,000	-3,199,000	-4,504,000	-3,096,000	-3,997,000	21,229,000	-4,000,000	-2,958,000	-1,906,000	-2,270,000	-3,785,000	-3,399,000	-1,975,000	-1,814,000	-1,625,000	-1,844,000	-2,162,000	-2,519,000	-2,881,000	1,180,000	-1,622,000	13,608,000	-1,461,000	-1,323,000	-925,000	-1,161,000	-1,871,000	-1,006,000	-4,593,000
cash flows from investing activities:
purchases of marketable securities	-53,944,000	-39,424,000	-164,078,000	-49,230,000			-49,265,000	0	-2,921,000	-2,930,000	-13,498,000	-33,530,000	-29,794,000	-62,293,000																		0	1,000	-3,000,000	-2,053,000	-7,275,000	-4,399,000	-3,308,000	-2,535,000	-1,545,000	-5,390,000	-3,036,000	-251,000	-250,000				0	-3,173,000	-1,786,000	-2,799,000	-3,154,000	-5,323,000	-3,184,000	-3,731,000	-5,030,000	-4,905,000
sales and maturities of marketable securities	103,500,000	79,225,000	68,500,000	67,000,000	25,500,000	22,000,000	3,000,000	0	16,784,000	35,500,000	47,000,000	41,000,000	30,000,000	6,000,000
purchases of property and equipment	-1,220,000	-276,000	-384,000	-1,574,000	-900,000	-1,194,000	-883,000	-1,720,000	-396,000	-484,000	-585,000	-1,198,000	-218,000	-149,000	0	-131,000			-192,000	-128,000	-26,000	-16,000	-6,000	0	-25,000	-182,000	-109,000	-45,000	1,000	0	-64,000	-126,000	-16,000			-46,000	-31,000	-25,000	-11,000	-90,000	-43,000	-22,000	-6,000	-173,000	-54,000	-13,000	-8,000	-19,000	-13,000	-32,000	-4,000	-6,000	-19,000	-159,000	-221,000	-65,000	-9,000					-21,000	-18,000	-49,000	-107,000	-139,000	-44,000	4,678,000	-4,767,000
net cash from investing activities	48,336,000	39,525,000	-95,962,000	16,196,000	-160,395,000	20,806,000	-47,148,000	-1,720,000	13,467,000	32,086,000	32,917,000	6,272,000	-12,000	-56,442,000	-32,965,000	-131,000			-192,000	-128,000	-26,000	-16,000	-6,000	0	-25,000	-182,000	-109,000	-1,753,000	-15,071,000	0	-64,000	2,374,000	3,335,000	2,388,000	5,480,000	-5,321,000	1,433,000	-28,000	-546,000	-885,000	-2,783,000	-3,058,000	-7,000	-421,000	-2,264,000	1,309,000	1,442,000	2,281,000	560,000	2,870,000	647,000	91,000	108,000	959,000	-552,000	-1,606,000	-2,555,000					-21,000	-18,000	-49,000	-107,000
cash flows from financing activities:
payment of equity issue costs	0	-291,000	-365,000	0	-218,000	-89,000
net settlement of stock units to satisfy statutory tax withholding	-19,000	-1,218,000	0	-78,000	-78,000	-4,356,000	0	0	0	-169,000	-24,000	0	-21,000	-250,000	-5,000	-5,000	-12,000	-128,000	0	0	-71,000	-19,000	-33,000	-41,000	-26,000	-20,000
proceeds from exercise of stock options and employee stock purchase plan	273,000	593,000					2,321,000													107,000	0	187,000
principal payments on finance lease obligations	-16,000	-35,000	-32,000				0	0	-18,000	-18,000	-34,000	-36,000	-34,000	-33,000	-44,000	-44,000	-40,000	-18,000	-14,000	-15,000	-13,000	-7,000
net cash from financing activities	238,000	-951,000	151,685,000	11,893,000	329,000	115,000	218,485,000	10,362,000	-36,658,000	-5,119,000	-58,000	92,000	-276,000	-448,000	108,516,000	-2,000	-381,000	108,769,000	10,480,000	4,904,000	1,662,000	20,446,000	1,945,000	2,371,000	17,914,000	11,634,000	28,863,000	30,266,000	23,361,000	6,081,000	963,000	6,099,000	2,395,000	0	9,000	122,000	16,530,000	329,000	9,000	0	0	179,000	56,000	-14,000	7,457,000	1,620,000	9,981,000	0	0	-66,000	4,735,000	0	0	0	114,000	-21,000		0
net increase in cash, cash equivalents and restricted cash	-14,015,000	-14,546,000	19,874,000	-10,939,000	-180,244,000	-10,250,000	148,228,000	-6,562,000	33,832,000	10,132,000	20,271,000	-6,772,000	-19,411,000	-77,048,000	58,883,000	-7,920,000	-10,949,000	93,670,000	16,183,000	5,912,000	-3,485,000	4,085,000	-9,546,000	-12,401,000	782,000	-1,882,000	16,988,000
cash, cash equivalents and restricted cash at beginning of period	0	99,854,000	0	0	0	281,413,000		0	0	95,783,000		0	0	178,743,000						0	0	22,364,000		0	0	45,411,000	38,926,000
cash, cash equivalents and restricted cash at end of period	-14,015,000	85,308,000	19,874,000	-10,939,000	-180,244,000	271,163,000		-6,562,000	33,832,000	105,915,000		-6,772,000	-19,411,000	101,695,000						5,912,000	-3,485,000	26,449,000		-12,401,000	782,000	43,529,000	55,914,000
reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets:
cash and cash equivalents	-14,015,000	85,158,000	19,874,000	-10,939,000	-180,244,000	271,013,000	148,228,000	-6,562,000	33,832,000	105,765,000
restricted cash	0	150,000	0	0	0	150,000	0	0	0	150,000
total cash, cash equivalents and restricted cash at end of period	-14,015,000	85,308,000	19,874,000	-10,939,000	-180,244,000	271,163,000		-6,562,000	33,832,000	105,915,000
supplemental disclosure of non-cash investing and financing activities:
lease liability arising from obtaining right-of-use assets	0	903,000	0	-112,000
property and equipment additions in accounts payable and accrued expenses	-53,000	96,000		-79,000	-315,000	535,000
stock issuance costs in accounts payable and accrued expenses	0	20,000
reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
benefit from excess and obsolete inventory							0	0
loss on extinguishment of debt							0	0						1,559,000									0	0	0	3,810,000																																											23,361,000
proceeds from issuance of stock			151,521,000				216,200,000																																																											0
payment of long-term debt							0	0			0	0	0	-38,235,000
payment of extinguishment of debt costs							0	0			0	0	0	-2,294,000									0	0	0	-2,716,000
borrowings under revolving facility							0	0	0	5,300,000	11,466,000	10,475,000	10,475,000	11,459,000
repayment under revolving facility							0	0	-5,295,000	-10,480,000	-11,466,000	-10,475,000	-10,475,000	-984,000
supplemental cash flow information:
cash interest paid							0	0	665,000	740,000	693,000	558,000	408,000	941,000	1,222,000	1,221,000	1,208,000	1,195,000	1,600,000	2,611,000	9,000	1,290,000	1,296,000	2,399,000	64,000	1,111,000	583,000
stock issuance costs						218,000	306,000										-264,000	329,000				295,000																							-32,000	79,000	39,000				67,000															-2,000
depreciation and amortization
proceeds from exercise of stock options				251,000	625,000	4,560,000			5,000	248,000	0	154,000	0	241,000	89,000	101,000	0	183,000					106,000	0	44,000	264,000									9,000				9,000				56,000
amortization of intangible assets											205,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	615,000	0	184,000	182,000	182,000	179,000	180,000	183,000	187,000	187,000	190,000	192,000	191,000	190,000	193,000	196,000	196,000	196,000	194,000	192,000	191,000	192,000	193,000	193,000	193,000	192,000	819,000	833,000	840,000	829,000	790,000	815,000	840,000	844,000	811,000	771,000	820,000	934,000	960,000	962,000	-20,387,000	22,351,000
impairment of intangible assets																																																				0	0																45,278,000
proceeds from issuance of long-term debt											0	0	0	30,000,000									0	0	15,000,000	35,000,000		5,000,000
payment of equity and debt issue costs							-36,000				0	-26,000	-221,000	-352,000
cash, cash equivalents and restricted cash at beginning of year															0	0	0	45,059,000
cash, cash equivalents and restricted cash at end of year															58,883,000	-7,920,000	-10,949,000	138,729,000
reconciliation of cash, cash equivalents and restricted cash
total cash, cash equivalents and restricted cash
accrued term loan exit fee											0	0	0	600,000									0	0	900,000	2,100,000		300,000
debt issue costs													-218,000	244,000												222,000
gain on extinguishment of debt																0
proceeds from issuance of stock and pre-funded warrants, net of issuance costs
payments forgiven under paycheck protection program loan															0	0
(gain) loss on extinguishment of debt												0
principal portion of finance lease liabilities																		12,000				7,000
amortization of debt discount															166,000	162,000	153,000	147,000	211,000	186,000	177,000	171,000	166,000	160,000	130,000	140,000	154,000
non-cash interest expense																			0	330,000	324,000	323,000	324,000	322,000	294,000	112,000																																								0	206,000	-456,000	757,000
benefit from excess and obsolescence inventory
proceeds under paycheck protection program loan																			0	0
payment of long-term debt principal																							0	0	0	-20,000,000
effect of foreign exchange rate changes on cash and cash equivalents																												-2,000	0	0	4,000	6,000	-1,000	-2,000	-8,000	-8,000	-4,000	-5,000	-3,000	5,000	-7,000	-5,000	-5,000	-1,000	-5,000	1,000	1,000	0	-9,000	-1,000	2,000	-3,000	2,000	-2,000	-3,000	-2,000	6,000	4,000	-15,000	5,000	-11,000	41,000	41,000	-127,000	-34,000	2,000	-35,000	133,000	-144,000
proceeds from issuance of stock, net of issuance costs																-54,000	-329,000	108,732,000	25,116,000	4,812,000	-295,000	20,285,000	1,872,000	2,412,000				25,205,000	9,266,000	6,081,000	963,000					-10,000								-92,000	7,005,000	1,163,000	9,981,000	0	0	-66,000	4,735,000
supplemental disclosure of non-cash financing activities:
payment of debt issue costs																							0	0	-447,000	-894,000		-442,000
payment of contingent development milestone																							0	0
amortization of bond (discount) premium on marketable securities																																0	-2,000	-2,000	-5,000
amortization of noncurrent portion of deferred revenue																																-1,000	1,000
change in fair value of derivative liability																											18,886,000	23,953,000
deferred rent																											38,000	-7,000	-4,000	-5,000	-4,000	-4,000	-2,000	-1,000	-2,000	0	1,000	2,000	2,000	2,000	6,000	5,000	5,000	26,000
maturities of marketable securities																																2,500,000	3,350,000	5,393,000	7,500,000	2,000,000	5,863,000	3,305,000	2,000,000	750,000	2,650,000	0	250,000	0	500,000	1,400,000	1,450,000	2,300,000	3,746,000	4,688,000	3,450,000	3,250,000	5,450,000	3,199,000	3,400,000	3,489,000	2,359,000
acquisition of icon bioscience inc., net of cash acquired																												-1,708,000
proceeds from sale of property and equipment																																0	0	0	33,000									2,000	4,000																								388,000
proceeds from exercise of warrants																											28,863,000
accrued development milestone																												0
fair value of second tranche purchase liability																												0
fair value of warrants issued with debt																												-5,000
fair value of second tranche warrants
accrued acquisition costs
stock-based compensation expense																											1,397,000		443,000	606,000	681,000		644,000	396,000	734,000		661,000	483,000	405,000		614,000	417,000	309,000		441,000	305,000	217,000		312,000	263,000	343,000		379,000	165,000	477,000		574,000		389,000	420,000	293,000				94,000	608,000
accounts and other receivables
prepaid expenses and other current assets
accounts payable
accrued expenses
supplemental disclosure of non-investing and financing activities:
adjustments to reconcile net income to cash flows from operating activities:
amortization of bond discount on marketable securities
changes in current assets and liabilities:
exercise of stock options																																	90,000				20,000				0				452,000								0	0	114,000
net decrease in cash and cash equivalents																													3,470,000	1,043,000	-5,065,000			-2,623,000	-1,005,000				-5,033,000														-2,033,000	-1,403,000	-3,101,000		5,919,000		-1,158,000	-834,000	-936,000
cash and cash equivalents at beginning of period																													0	0	16,898,000		0	0	15,313,000		0	0	19,121,000		0	0	15,334,000		0	0	6,899,000		0	0	4,625,000		0	0	12,912,000		0		0	0	6,899,000		0	0	15,609,000		0	2,354,000	316,000
cash and cash equivalents at end of period																													3,470,000	1,043,000	11,833,000		1,186,000	-2,623,000	14,308,000		13,657,000	-2,878,000	14,088,000		-6,744,000	18,367,000	11,384,000		3,336,000	673,000	14,546,000		-1,411,000	1,021,000	8,388,000		-2,033,000	-1,403,000	9,811,000		5,919,000		-1,158,000	-834,000	5,963,000		-1,830,000	-1,133,000	10,982,000		8,392,000	-6,671,000	16,454,000
net increase in cash and cash equivalents																																4,027,000				-9,554,000	13,657,000			-3,886,000	-6,744,000	18,367,000	-3,950,000	-3,221,000	3,336,000	673,000	7,647,000	-1,099,000	-1,411,000	1,021,000	3,763,000											-1,120,000	-1,830,000	-1,133,000	-4,627,000
cash and cash equivalents at beginning of year
cash and cash equivalents at end of year
supplemental disclosure of cash flow information:
cash paid for income taxes																																				0				0																0		96,000
issuance of stock, net of issue costs
amortization of bond premium on marketable securities																																				1,000	18,000	34,000	34,000	32,000	25,000	23,000	18,000	19,000	2,000	7,000	17,000	29,000	38,000	41,000	44,000	41,000	62,000	76,000	85,000	85,000	38,000
gain on sale of property and equipment																																												-2,000	-4,000
change in restricted cash																																												0	0
purchase of property and equipment
change in fair value of derivatives																																																				0	0	-128,000	-42,000	-10,000	-334,000	-871,000	-226,000	-83,000	1,519,000	619,000	-22,000	-226,000	-1,330,000	-1,164,000	-1,172,000	12,139,000	-18,160,000
deferred income tax benefit																																																														-31,000				-296,000	-15,000	25,115,000	-25,339,000
proceeds from sales of marketable securities																																																				1,000	0
deferred tax benefit																																																					0	0	-13,000
supplemental disclosure of non-cash investing activities:
proceeds from exercise of stock options and warrants
loss on sale of equipment
benefit from losses on note receivable																																																														0	0	667,000	633,000
foreign currency translation gains upon dissolution of subsidiaries
exercise of warrants																																																											0
patents and licences
gross carrying amount at beginning of period
foreign currency translation adjustments
gross carrying amount at end of period
accumulated amortization at beginning of period
amortization expense
accumulated amortization at end of period
net book value at end of period
impairment of goodwill
gain on sale of equipment
benefit from loss on note receivable
supplemental disclosure:
•
income from discontinued operations
gain on sale of discontinued operations
income from continuing operations
amortization of convertible note debt discount and issue costs																																																																					6,649,000
accounts, note and other receivables
net cash from operating activities of continuing operations
net cash from operating activities of discontinued operations
decrease (increase) in restricted cash
net cash from investing activities of continuing operations
net cash from investing activities of discontinued operations
proceeds from issuance of convertible notes																																																																					21,500,000
debt issuance costs																																																																					-1,894,000
repayment of convertible notes																																																																					-14,973,000
premium paid on extinguishment of debt																																																																					-3,034,000
proceeds from issuance of shares																																																																				-63,416,000	84,038,000
share issue costs																																																																				5,095,000	-7,330,000
share-based compensation expense																																																																				-2,796,000	2,882,000
accounts and note receivable and other current assets																																																																312,000	-55,000		-865,000	2,486,000	-2,822,000
cash flows from financing activities																																																																			0	-63,299,000	81,686,000
in-process research and development																																																																					26,244,000
gain on sale of fixed assets
net cash paid for acquisition of businesses, net of cash acquired																																																																					-5,836,000
depreciation and amortization of property and equipment																																																																			65,000	-4,412,000	4,667,000
cash flows used in operating activities
cash flows used in investing activities
net change in cash and cash equivalents																																																																			8,392,000	-9,025,000	16,138,000
cash flows from operating activities																																																																				45,868,000	-57,042,000
cash flows from investing activities																																																																				8,273,000	-8,362,000
gain on sale of subsidiary																																																																					-3,674,000
other																																																																					31,000
proceeds from sale of subsidiary																																																																					1,853,000
equity contribution from outside equity interest																																																																					3,379,000
receipts from customers
payments to suppliers, employees and consultants
interest received
income tax paid
research and development expenditure paid
income received in advance
other revenue received
interest paid
purchase of property, plant and equipment
proceeds from sale of property, plant and equipment
net cash paid for acquisition of business
net cash paid for increased interest in subsidiary
proceeds from issue of ordinary shares
payment of share issue and registration costs
proceeds from borrowings
payment of borrowing costs
net increase / (decrease) in cash and cash equivalents
cash and cash equivalents at the beginning of the financial year
effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies
cash and cash equivalents at the end of the financial year

We provide you with 20 years of cash flow statements for EyePoint Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of EyePoint Pharmaceuticals stock. Explore the full financial landscape of EyePoint Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about EyePoint Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.